CD86 and neoplasm: Given that previous studies have documented the release of DAMPs capable of driving CD86 expression on BMDC in vitro 34, as well as antigen-agnostic activation of DCs after BH in mouse lymphoma 12, we had expected a similar global activation of cDCs independent from the acquisition of tumor antigen.